{"id":66693,"date":"2026-05-29T14:29:49","date_gmt":"2026-05-29T06:29:49","guid":{"rendered":"https:\/\/flcube.com\/?p=66693"},"modified":"2026-05-29T14:29:50","modified_gmt":"2026-05-29T06:29:50","slug":"innovent-biologics-and-pfizer-forge-10-5b-global-oncology-partnership-spanning-12-first-in-class-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66693","title":{"rendered":"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Innovent Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) and <strong>Pfizer<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) have announced a landmark <strong>$10.5 billion global strategic partnership<\/strong> encompassing <strong>12 early-stage, first-in-class oncology discovery and R&amp;D programs<\/strong> with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-financial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>$650 million<\/td><td>Paid to Innovent by Pfizer<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to $9.85 billion<\/td><td>Development, regulatory, and commercial milestones<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>$10.5 billion<\/strong><\/td><td>One of the largest China-U.S. biopharma partnerships<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Up to double-digit tiered<\/td><td>On net sales for each approved product<\/td><\/tr><tr><td><strong>Profit Sharing<\/strong><\/td><td>50\/50<\/td><td>For co-development programs in U.S. and Europe<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-portfolio-composition\" class=\"wp-block-heading\">Portfolio Composition<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>8 Early-Stage Assets:<\/strong> From Innovent&#8217;s proprietary pipeline<\/li>\n\n\n\n<li><strong>4 De Novo Programs:<\/strong> To be proposed by Pfizer<\/li>\n\n\n\n<li><strong>Therapeutic Modalities:<\/strong><\/li>\n\n\n\n<li>Multiple <strong>antibody-drug conjugates (ADCs)<\/strong> with novel, differentiated payloads<\/li>\n\n\n\n<li><strong>Multispecific antibodies<\/strong> featuring unique immunomodulatory properties and structural designs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-geographic-rights-amp-development-framework\" class=\"wp-block-heading\">Geographic Rights &amp; Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program Category<\/th><th>Quantity<\/th><th>Geographic Rights<\/th><th>Cost Sharing<\/th><th>Commercial Rights<\/th><\/tr><\/thead><tbody><tr><td><strong>Co-Development\/Co-Commercialization<\/strong><\/td><td>4 programs<\/td><td>Worldwide development<\/td><td>50\/50 shared<\/td><td><strong>U.S.\/Europe<\/strong>: 50\/50 profit share<br><strong>Greater China<\/strong>: Innovent retains<\/td><\/tr><tr><td><strong>Pfizer Exclusive (ex-China)<\/strong><\/td><td>4 programs<\/td><td>Outside Greater China<\/td><td>Pfizer majority<\/td><td>Pfizer exclusive outside Greater China<\/td><\/tr><tr><td><strong>Global Pfizer Exclusive<\/strong><\/td><td>4 programs<\/td><td>Worldwide<\/td><td>Pfizer covers all<\/td><td>Pfizer global exclusive<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-innovent-biologics\" class=\"wp-block-heading\">For Innovent Biologics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Validation:<\/strong> Partnership with pharmaceutical giant validates Innovent&#8217;s innovation capabilities<\/li>\n\n\n\n<li><strong>Capital Infusion:<\/strong> $650M upfront provides substantial runway for other pipeline programs<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Shared development costs reduce financial burden on capital-intensive oncology programs<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Leverages Pfizer&#8217;s established commercial infrastructure in key Western markets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-pfizer\" class=\"wp-block-heading\">For Pfizer<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Access to cutting-edge Chinese biotech innovation in ADCs and multispecific antibodies<\/li>\n\n\n\n<li><strong>First-in-Class Potential:<\/strong> Programs designed to address unmet needs with novel mechanisms of action<\/li>\n\n\n\n<li><strong>Geographic Expansion:<\/strong> Strengthens presence in Greater China through partnership with local leader<\/li>\n\n\n\n<li><strong>Innovation Pipeline:<\/strong> Addresses need for next-generation oncology assets beyond current portfolio<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Biotech Maturity:<\/strong> Represents evolution from licensing foreign drugs to China toward global innovation partnerships<\/li>\n\n\n\n<li><strong>ADC Market Dynamics:<\/strong> Highly competitive space with major players including AstraZeneca, Daiichi Sankyo, and ImmunoGen<\/li>\n\n\n\n<li><strong>Multispecific Antibodies:<\/strong> Emerging modality with significant clinical and commercial potential<\/li>\n\n\n\n<li><strong>Cross-Border Collaboration:<\/strong> Increasing trend of U.S.-China partnerships despite geopolitical tensions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership terms, development timelines, and financial projections. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, market competition, and geopolitical factors affecting U.S.-China business relationships.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,910,198,28,863,309],"class_list":["post-66693","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-hkg-1801","tag-innovent-biologics","tag-multi-specific-antibodies","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global strategic partnership encompassing 12 early-stage, first-in-class oncology discovery and R&amp;D programs with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66693\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global strategic partnership encompassing 12 early-stage, first-in-class oncology discovery and R&amp;D programs with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66693\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T06:29:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T06:29:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66693#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66693\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs\",\"datePublished\":\"2026-05-29T06:29:49+00:00\",\"dateModified\":\"2026-05-29T06:29:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66693\"},\"wordCount\":408,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"HKG: 1801\",\"Innovent Biologics\",\"Multi-specific antibodies\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66693#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66693\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66693\",\"name\":\"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T06:29:49+00:00\",\"dateModified\":\"2026-05-29T06:29:50+00:00\",\"description\":\"Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global strategic partnership encompassing 12 early-stage, first-in-class oncology discovery and R&D programs with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66693#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66693\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66693#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global strategic partnership encompassing 12 early-stage, first-in-class oncology discovery and R&D programs with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66693","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs","og_description":"Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global strategic partnership encompassing 12 early-stage, first-in-class oncology discovery and R&D programs with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.","og_url":"https:\/\/flcube.com\/?p=66693","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T06:29:49+00:00","article_modified_time":"2026-05-29T06:29:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66693#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66693"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs","datePublished":"2026-05-29T06:29:49+00:00","dateModified":"2026-05-29T06:29:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66693"},"wordCount":408,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","HKG: 1801","Innovent Biologics","Multi-specific antibodies","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66693#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66693","url":"https:\/\/flcube.com\/?p=66693","name":"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T06:29:49+00:00","dateModified":"2026-05-29T06:29:50+00:00","description":"Innovent Biologics (HKG: 1801) and Pfizer (NYSE: PFE) have announced a landmark $10.5 billion global strategic partnership encompassing 12 early-stage, first-in-class oncology discovery and R&D programs with breakthrough potential. The deal combines licensing, co-development, and co-commercialization models across a diverse portfolio of innovative cancer therapeutics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66693#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66693"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66693#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66693"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66693\/revisions"}],"predecessor-version":[{"id":66694,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66693\/revisions\/66694"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}